GlobalData's clinical
trial report, “Alzheimer's Disease Global
Clinical Trials Review, H2, 2016" provides an overview of Alzheimer's
Disease clinical trials scenario. This report provides top line data relating
to the clinical trials on Alzheimer's Disease. Report includes an overview of
trial numbers and their average enrollment in top countries conducted across
the globe. The report offers coverage of disease clinical trials by region,
country (G7 & E7), phase, trial status, end points status and sponsor type.
Report also provides prominent drugs for in-progress trials (based on number of
ongoing trials).
Browse the complete report at
http://www.acutemarketreports.com/report/alzheimers-disease-global-clinical-trials-review-h2-2016
GlobalData Clinical
Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database.
Clinical trials are collated from 80+ different clinical trial registries,
conferences, journals, news etc across the globe. Clinical trials database
undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Browse All Reports of This Category:
http://www.acutemarketreports.com/category/healthcare-market
Scope:
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Browse Full Report Click here:
http://www.acutemarketreports.com/report/alzheimers-disease-global-clinical-trials-review-h2-2016
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table of Content:
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Alzheimer's Disease 31
Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer’s Disease to Phase III 31
Aug 02, 2016: Accera Appoints C. Evan Ballantyne as Chief Financial Officer 31
Aug 01, 2016: The results of phase I clinical trial of the Araclon Biotech Alzheimers vaccine support its continuation 32
Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016 32
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Alzheimer's Disease 31
Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer’s Disease to Phase III 31
Aug 02, 2016: Accera Appoints C. Evan Ballantyne as Chief Financial Officer 31
Aug 01, 2016: The results of phase I clinical trial of the Araclon Biotech Alzheimers vaccine support its continuation 32
Jul 29, 2016: Anavex Confirms Data from Phase 2a Study of ANAVEX 2-73 in Alzheimer's Patients Presented at AAIC 2016 32
Latest Reports:
·
http://www.acutemarketreports.com/report/united-arab-emirates-orthobiologics-market-outlook-to-2022
About – Acute Market Reports:
Acute
Market Reports is the most sufficient collection of market intelligence
services online. It is your only source that can fulfill all your market
research requirements. We provide online reports from over 100 best publishers
and upgrade our collection regularly to offer you direct online access to the
world’s most comprehensive and recent database with expert perceptions on
worldwide industries, products, establishments and trends.
Our
team consists of highly motivated market research professionals and they are
accountable for creating the groundbreaking technology that we utilize in our
search engine operations to easily recognize the most current market research
reports online.
Contact Us:
Chris Paul
ACUTE MARKET REPORTS
Office No 101, 1st Floor ,
Aditi Mall, Baner,
Pune, MH, 411045
India
Toll Free(US/CANADA): +1-855-455-8662
No comments:
Post a Comment